June 27, 2024
Date: Jun 27, 2024
Duration: 1 Hr
Sponsored by WuXi Biologics
This webcast features: Tongdan Wang, PhD, Senior Director, Analytical Sciences, WuXi Biologics & Xinyuan Lu, PhD, Senior Director, Analytical Sciences, WuXi Biologics.
In the rapidly evolving landscape of biologics, especially for new modalities like antibody drug conjugates (ADCs) and bispecific/multi-specific antibodies, detailed product characterization evaluation and appropriate potency assessment are crucial for ensuring product quality control and fulfilling regulatory requirements.
This webinar will dive deeper into the following topics:
Deciphering Protein Structure: Advancing Biologics Development Through Product Characterization
Analyze the biologics primary structure, such as CIEF-MS and sequence variant analysis toolboxes, with novel technologies.
Discover tailored approaches for in-depth characterization of ADC, BsAb, and more.
Examine phase-appropriate product characterization strategies during bioprocess development.
Revealing Biologics Efficacy: Advanced Strategies for Potency Assay Development for Multi-Specific Drugs
Learn about risk assessment and mitigation strategies for potency assay development across all drug development stages.
Delve into case studies highlighting potency method development for challenging new modalities including ADC, probodies, BsAb, and MsAbs.
Thank you for your interest in this webcast. You may submit your request to view the webcast, and you will receive a confirmation email with log-in details.
You May Also Like
